|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Wisconsin Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing WisconsinLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Arrowhead Pharmaceuticals, Inc.
| | | Phone: | (608) 316-3890 | Fax: | (608) 441-0741 | Year Established: | 2003 | Ticker: | ARWR | Exchange: | NASDAQ | Main Contact: | Peter B. Leone, MBA, VP, Strategic Business Initiatives | | Other Contacts: | Zhen Li, Ph.D., Senior VP, Chemistry and Non-Clinical Development Patrick O’Brien, J.D., PharmD, General Counsel Bruce Given, M.D, COO Ken Myszkowski, MBA, CPA, CFO Christopher Anzalone, Ph.D., President & CEO
| | Company Description | Arrowhead Pharmaceuticals, formerly Arrowhead Research, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. | |
|
|
|
|
|